Objective To explore the therapeutic effect of secukinumab combined with fluticasone propionate cream in patients with psoriasis vulgaris and its influence on the degree of skin lesions and inflammatory response. Methods Forty patients with psoriasis vulgaris admitted to our hospital from January 2022 to May 2023 were randomly divided into control group and experimental group, with 20 patients in each group. The control group was treated with calcipotriol ointment+fluticasone propionate cream, and the experimental group was treated with scocuziumab combined with fluticasone propionate cream. The clinical efficacy, degree of skin lesions and levels of inflammatory factors were compared between the two groups. Results The total effective rate of treatment in the experimental group was 95.00%, which was higher than 70.00% in the control group (P <0.05). After treatment, the skin lesion area of head and neck, upper limbs, trunk and lower limbs and the severity scores of erythema, infiltration and scales in the experimental group were lower than those in the control group (P <0.05). After treatment, the levels of IL-17, IL-10 and IL- 22 in the experimental group were lower than those in the control group (P <0.05). Conclusion Secukinumab combined with fluticasone propionate cream can effectively improve the clinical symptoms of patients with psoriasis vulgaris, improve the degree of skin lesions and reduce the body's inflammatory response, which is worthy of clinical use.